Clinical Trials Browser

Phase 2 × Leukemia, Myelomonocytic, Chronic × Imatinib Mesylate × Clear all

NCT00079313 2017-07-02

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Phase 2 Completed

7 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myelomonocytic, Chronic

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

Phase 2 Completed

38 enrolled

MyeloidOther hematologic neoplasmSarcomaThoracic

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT00136409 2016-12-23

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Phase 2 Completed

34 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT00039416 2014-02-25

Imatinib Mesylate in Treating Patients With Myelofibrosis

Phase 2 Completed

18 enrolled

MyeloidOther hematologic neoplasm

Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis